Dr David Stamler - CEO - Alterity Therapeutics Limited
(ASX:ATH) is developing first-in-class therapies to treat neurodegenerative disease. The company's lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
